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ABSTRACT
Background. The presence of extramural tumor deposits
without lymph node structure (EX) is an important prog-
nostic factor for patients with colorectal cancer. However,
the clinical significance of EX in the lateral pelvic lymph
node area (LP-EX) remains unclear. This study aimed to
determine the prognostic implications of LP-EX for
patients with low rectal cancer.
Methods. This retrospective study involved 172 consecu-
tive patients with stage 2 or 3 low rectal cancer who
underwent curative surgery including lateral pelvic lymph
node (LPLN) dissection. The patients were classified into
the following three groups according to the metastatic
status of the LPLN area: patients without metastasis (no-
LP-M group), patients with lymph node metastasis (LP-
LNM group), and patients with EX (LP-EX group).
Potential prognostic factors of overall survival (OS) and
relapse-free survival (RFS) were identified in uni- and
multivariate analyses.
Results. Classification assigned 131 patients (76 %) to the
no-LP-M group, 27 patients (16 %) to the LP-LNM group,
and 14 patients (8 %) to the LP-EX group. The 5-year OS
rate was 80.3 % in the no-LP-M group, 61.1 % in the LP-
LNM group, and 34.9 % in the LP-EX group (P\ 0.001).
The corresponding 5-year RFS rates were 62.2, 33.8, and
14.3 %, respectively (P\ 0.001). A multivariate Cox
proportional hazards regression analysis showed that the
presence of LP-EX was an independent prognostic factor
for OS (P = 0.006) and RFS (P = 0.001).
Conclusions. The LP-EX classification is a useful patho-
logic parameter that can be used to stratify patients with
metastasis in the LPLN area.
Lateral pelvic lymph node (LPLN) metastasis of low
rectal cancer is managed quite differently between Western
countries and Japan. Western countries generally consider
LPLN metastasis to be a systemic disease, and neoadjuvant
chemoradiotherapy (NACRT) followed by total mesorectal
excision (TME) is the standard treatment for low rectal
cancer.1–3 On the other hand, in Japan, LPLN metastasis is
regarded as a local disease, and TME with LPLN dissection
has been performed for patients with locally advanced low
rectal cancer.4,5 Large-scale retrospective studies in Japan
have evaluated the survival outcomes for patients with
LPLN metastasis, concluding that LPLN metastasis could
be regarded as a form of regional lymph node metastasis in
low rectal cancer.6
Previous reports have demonstrated that the incidence of
LPLN metastasis is 10 to 25 % among patients with low
rectal cancer 2,7,8 and that the presence of LPLN metastasis
is a poor prognostic factor.5,6,9 A retrospective Japanese
study of low rectal cancer showed that the overall survival
(OS) rate for patients with LPLN metastasis was signifi-
cantly lower than for patients with mesorectal lymph node
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metastasis.6 Hence, patients with LPLN metastasis should
be treated in a manner independent of that for patients who
have only mesorectal lymph node metastasis. Moreover, it
also may be useful to stratify LPLN metastases into several
subclassifications, which could provide further useful
information for tailor-made treatments.
Extramural tumor deposits without lymph node structure
(EX) have been investigated in studies of colorectal cancer for
two decades.10–17 The categorization of EX by the American
Joint Committee on Cancer (AJCC) has changed several
times. The AJCC 5th edition18 proposed the first categoriza-
tion of EX, determined on the basis of size. An EX with a
diameter greater than 3 mm was classified in the N category
as a lymph node metastasis, whereas an EX with a diameter
up to but not exceeding 3 mm was classified in the T category
as a discontinuous tumor extension. In contrast, the criteria for
EX categorization relied on contour in the AJCC 6th edi-
tion,19 which recommended that a tumor nodule be classified
in the N category if the nodule had a smooth contour and in the
T category if the nodule had an irregular contour.
Currently, the categorizations of EX according to size
and contour have been abandoned. Instead, the AJCC 7th
edition20 notes that a peritumoral deposit or satellite nodule
in the pericolic or perirectal fat (which may represent
discontinuous spread, extravascular spread, or a totally
replaced lymph node) is recorded as a tumor deposit (TD).
Regarding the treatment of TD in the tumor-node-metas-
tasis (TNM) classification, the AJCC 7th edition states that
totally replaced nodes should be counted separately as
positive nodes in the N category, whereas discontinuous
spread or venous invasion should be classified and counted
in the site-specific factor category. However, the AJCC 7th
edition does not comment on the site of EX. It has been
unclear whether TD should be categorized for all regional
lymph node areas, including the LPLN area.
In the current study, we clarified the clinical significance
of EX in the LPLN area (LP-EX) and elucidated the
optimal categorization of LP-EX in patients with low rectal
cancer. We enrolled 172 consecutive patients who had
undergone LPLN dissection with TME and analyzed their




This retrospective study involved 172 consecutive
patients with stage 2 or 3 low rectal cancer who underwent
R0 resection that included both TME and LPLN dissection
at Niigata University Medical and Dental Hospital or Nii-
gata Cancer Center Hospital between January 2000 and
December 2012. Patients with histologically confirmed
adenocarcinoma were selected from our colorectal data-
bases according to the AJCC 7th edition.10
In the current study, low rectal cancer was defined as
tumor with the distal edge located at or below the peritoneal
reflection. We did not apply NACRT at our institutions
during the study period because it remains controversial
whether this approach improves OS or contributes to the
benefits of sphincter-preserving surgery.21 After TME with
LPLN dissection, the patients were followed up by physical
and laboratory testing, as well as by imaging. Recurrences
were classified as local or distant according to the Japanese
Society for Cancer of the Colon and Rectum (JSCCR)
classification.22 Local recurrence was defined as any tumor
recurrence within the true pelvis or anal canal. Distant
recurrence was defined as any tumor recurrence outside the
pelvis. Carcinoembryonic antigen and carbohydrate antigen
19–9 were monitored periodically. Disease recurrence was
mainly determined by chest-abdominal-pelvic computed
tomography scans. Colonoscopy was performed to detect
local recurrence at the anastomotic site.
The current study included 122 men and 50 women with a
median age of 63 years (range, 17–81 years). Of these 172
patients, 103 received postoperative adjuvant chemotherapy,
with 97 receiving 5-fluorouracil (5-FU)- based adjuvant
chemotherapy (5-FU, 5-FU/leucovorin, 5-FU/mitomycin C,
tegafur-uracil/leucovorin, tegafur-gimeracil-oteracil potas-
sium capsule, doxifluridine, or 1-hexylcarbamoyl-5-fluorou
racil) and 6 receiving oxaliplatin-based adjuvant chemother-
apy (5-FU/leucovorin plus oxaliplatin [FOLFOX] or cape
citabine plus oxaliplatin [CapeOX]). On the other hand, 69
patients received no adjuvant chemotherapy. The median
follow-up period for the 172 patients was 49.5 months (range,
0.4–168.9 months) (Table 1). This study was approved by the
institutional review board at each institution.
Anatomy of the LPLN Area and Indication for LPLN
Dissection
The LPLN area was divided into the following five areas
according to the JSCCR classification: proximal internal
iliac, distal internal iliac, obturator, common iliac, and
external iliac (Fig. 1a).22 The indication for LPLN dis-
section followed the JSCCR Guidelines. The lower border
of the tumor was located distal to the peritoneal reflection,
and the tumor invaded beyond the muscularis propria.23
After TME, bilateral LPLN dissection was performed in
accordance with previously reported methods.4,5
Pathologic Examination of LP-EX
After the surgery, surgeons harvested both mesenteric
lymph nodes and LPLNs from fresh surgical specimens.
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Thereafter, the bowel specimen, mesenteric lymph nodes,
and LPLNs were fixed in 10 % formalin and sent to the
pathology department for routine pathologic examination.
In the current study, LP-EX was defined as a tumor
nodule in the LPLN area without histopathologic evidence
of residual lymph node structure (Fig. 1b). The LP-EX
classification included venous invasion with extravascular
spread, a totally replaced node, and discontinuous cancer
spread of unknown origin in the LPLN area. One of the
authors (Yoshifumi Shimada) retrospectively reexamined
all slides of harvested LPLNs and subclassified the
metastases in the LPLN area (LP-M) into ‘‘lymph node
metastasis’’ (LP-LNM) or ‘‘EX’’ (LP-EX).
Definitions of the No-LP-M, LP-LNM, and LP-EX
Groups
The 172 patients in the current study were classified into
three groups according to the pathologic status of the
LPLN area. The patients without metastasis in the LPLN
area were defined as the ‘‘no lateral pelvic metastasis’’ (no-
LP-M) group. The patients with metastasis in the LPLN
area were subclassified into two groups (LP-LNM and LP-
EX groups). The LP-LNM group comprised patients who
had LP-LNM without LP-EX, whereas the LP-EX group
consisted of patients who had LP-EX with or without LP-
LNM. In other words, the definition of the LP-EX group
included patients with LP-EX alone as well as patients with


















FIG. 1 Lymph nodes of the lateral pelvic area. a Extramural tumor
deposit without lymph node structure (hematoxylin and eosin; 91). b.
A, B, C, D, and E denote proximal internal iliac nodes, distal internal
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FIG. 2 Overall survival curves according to the status of lateral
pelvic metastasis. a Relapse-free survival curves according to the
status of lateral pelvic metastasis. b No lateral pelvic-metastasis (no-
LP-M), lateral pelvic-lymph node metastasis (LP-LNM), and lateral
pelvic-extramural tumor deposit (LP-EX)
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Prognostic Factors
To elucidate the factors influencing OS and relapse-free
survival (RFS) after TME with LPLN dissection, the follow-
ing nine clinicopathologic variables were tested in all 172
patients: age (\65 vs C65 years), sex, tumor size (\60 vs
C60 mm), T category (T2 and T3 vs T4), histopathologic grade
(G1 vs G2 and G3), lymphatic invasion (absence vs presence),
venous invasion (absence vs presence), N category (N0 vs N1
and N2), and LP-M (no-LP-M vs LP-LNM vs LP-EX).
Statistical Analyses
Statistical analyses were performed with IBM SPSS
Statistics 22 (IBM Japan Inc., Tokyo, Japan). The relation-
ships between each of the clinicopathologic variables and
the pathologic status of the LPLN area were analyzed using
the Chi square test. The 5-year OS, RFS, and cumulative
local recurrence rates were estimated using the Kaplan–
Meier method. The log-rank test was used to assess the
statistical significance of differences between subgroups in
univariate analyses. Factors with P values \0.05 in the
univariate analyses were entered into the multivariate anal-
yses. In the multivariate analyses, the Cox proportional
hazards regression model was used to identify factors
independently associated with OS and RFS after surgery. All
P values\0.05 were considered statistically significant.
RESULTS
Anatomic Sites of LP-LNM
In 54 nodes found in 32 (18.6 %) of the 172 patients,
LP-LNM was observed. These 32 patients were assigned to
the LP-LNM group or the LP-EX group. The 27 patients
with LP-LNM alone were assigned to the LP-LNM group,
and the five patients with both LP-LNM and LP-EX were
assigned to the LP-EX group. The sites and frequencies of
LP-LNM were as follows: proximal internal iliac nodes (2
nodes), distal internal iliac nodes (35 nodes), obturator
nodes (12 nodes), common iliac nodes (5 nodes), and
external iliac nodes (0 nodes).
TABLE 1 Association between the status of the LPLN area and other clinicopathologic variables
Variable No-LP-M LP-LNM LP-EX P value
(n = 131) (n = 27) (n = 14)
Age (years)
\65 76 14 6 0.501
C65 55 13 8
Sex
Male 94 21 7 0.163
Female 37 6 7
Tumor size (mm)
\60 73 18 6 0.329
C60 58 9 8
T category
T2, T3 117 23 12 0.788
T4 14 4 2
Histopathologic grade
G1 22 1 0 0.059
G2, G3 109 26 14
Lymphatic invasion
Absence 46 4 1 0.017
Presence 85 23 13
Venous invasion
Absence 44 6 0 0.022
Presence 87 21 14
N category
N0 52 0 0 \0.001
N1, N2 79 27 14
LP-M lateral pelvic-metastasis, LP-LNM lateral pelvic-lymph node metastasis, LP-EX lateral pelvic-extramural tumor deposits
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Anatomic Sites of LP-EX
In 14 (8.1 %) of the 172 patients, 23 foci of LP-EX were
observed. Each of these 14 patients was assigned to the LP-EX
group. The sites and frequencies of LP-EX were as follows:
proximal internal iliac nodes (1 focus), distal internal iliac
nodes (14 foci), obturator nodes (6 foci), common iliac nodes
(2 foci), and external iliac nodes (0 foci).
Association Between the Pathologic Status of the LPLN
Area and Other Clinicopathologic Variables
The status of the LPLN area was significantly associated
with lymphatic invasion (P = 0.017), venous invasion
(P = 0.022), and N category (P\ 0.001), whereas no
significant associations were observed between the status
of the LPLN area and the other clinicopathologic variables
(Table 1).
Factors Influencing OS and RFS
The 5-year OS rates after TME with LPLN dissection
were 80.3 % in the no-LP-M group, 61.1 % in the LP-
LNM group, and 34.9 % in the LP-EX group (Fig. 2a). The
univariate analyses showed that N category and LP-M were
significant prognostic factors for OS (P = 0.006 and
\0.001, respectively). These significant variables were
entered into a multivariate analysis, which identified LP-
EX as a significant independent prognostic factor for OS
(P = 0.006) (Table 2).
The 5-year RFS rates after TME with LPLN dissection
were 62.2 % in the no-LP-M group, 33.8 % in the LP-
LNM group, and 14.3 % in the LP-EX group (Fig. 2b). The
univariate analyses showed that T category, N category,
and LP-M were significant prognostic factors for RFS
(P = 0.009, 0.015,\0.001, respectively). These significant
variables were entered into a multivariate analysis, which
identified T category and LP-EX as significant independent
prognostic factors for RFS (P = 0.010 and 0.001, respec-
tively) (Table 2).
Cumulative Local Recurrence
The 5-year cumulative local recurrence rates after TME
with LPLN dissection were 9.2 % in the no-LP-M group,
26.8 % in the LP-LNM group, and 28.6 % in the LP-EX
group. The cumulative local recurrence rate in the LP-EX
group was significantly greater than in the no-LP-M group
(P = 0.009), whereas no significant difference was
observed between the LP-LNM and LP-EX groups.
TABLE 2 Uni- and multivariate analyses of different prognostic factors for overall survival and relapse-free survival










Age (years) \65 96 77.9 0.231 55.1 0.800
C65 76 67.8 50.8
Sex Male 122 73.7 0.529 56.5 0.620
Female 50 72.7 46.5
Tumor size (mm) \60 97 76.6 0.431 52.2 0.773
C60 75 69.7 54.6
T category T2, T3 152 73.7 0.531 56.4 0.009 1.00
T4 20 71.5 30.5 2.22 (1.21–4.07) 0.010
Histopathologic grade G1 23 84.4 0.127 64.4 0.217
G2, G3 149 71.7 52.4
Lymphatic invasion Absence 51 82.5 0.223 51.9 0.883
Presence 121 70.1 53.8
Venous invasion Absence 50 75.7 0.871 51.4 0.868
Presence 122 72.8 54.2
N category N0 52 89.2 0.006 1.00 65.8 0.015 1.00
N1, N2 120 67.1 2.36 (0.95–5.85) 0.064 47.7 1.52 (0.82–2.82) 0.184
LP-M No-LP-M 131 80.3 \0.001 1.00 62.2 \0.001 1.00
LP-LNM 27 61.1 1.77 (0.83–3.76) 0.141 33.8 1.67 (0.89–3.11) 0.108
LP-EX 14 34.9 3.16 (1.39–7.17) 0.006 14.3 3.05 (1.55–5.98) 0.001
OS overall survival, HR hazard ratio, CI confidence interval, RFS relapse-free survival, LP-M lateral pelvic-metastasis, LP-LNM lateral pelvic-
lymph node metastasis, LP-EX lateral pelvic-extramural tumor deposit
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Pattern of Initial Recurrence in the LP-EX Group
Initial distant recurrences were significantly more likely
in the LP-EX group (9/14, 64.3 %) than in the other groups
(42/158, 26.6 %) (P = 0.006). In contrast, the rate of ini-
tial local recurrences did not differ significantly between
the LP-EX group (3/14, 21.4 %) and the other groups (15/
158, 9.5 %) (P = 0.167).
DISCUSSION
The current study showed two main results concerning
LP-EX in patients with low rectal cancer. First, metastases
in the LPLN area could be subclassified as LP-LNM or LP-
EX, which were associated with significantly different
survival rates. Second, the multivariate analyses showed
that LP-EX was an independent prognostic factor. These
results indicate that patients with metastasis in the LPLN
area could be stratified in a simple manner according to the
morphologic evaluation of metastasis in the LPLN area and
that the presence of LP-EX might have an important role in
tailor-made treatment strategies.
The importance of lateral spreading in low rectal cancer
was first brought to the attention of the medical community
by Sauer and Bacon24 in 1951. In more recent years, sev-
eral studies have reported the clinical significance of LPLN
metastasis and have attempted to stratify patients with
LPLN metastasis.5,6,9,25–28 Ueno et al.27 demonstrated that
the number of LPLN metastases had a significant associ-
ation with prognosis: patients with two or more LPLN
metastases demonstrated a poorer prognosis than those
with only one LPLN metastasis. Akiyoshi et al.6 stratified
patients with LPLN metastasis according to anatomic
location, finding that patients with external LPLN metas-
tasis showed a worse prognosis than those with internal
LPLN metastasis. Komori et al.28 showed that extracap-
sular invasion in the LPLN area was an independent
prognosis factor correlated with OS and RFS rates. How-
ever, to date, no studies have addressed the clinical
significance of EX in the LPLN area. Hence, the current
study is the first to elucidate the clinical significance of LP-
EX.
To date, it has been unclear whether LP-LNM and LP-
EX have the same prognostic values. The current study
evaluated the prognostic value of LP-EX by comparing it
with that of LP-LNM and demonstrated that the 5-year OS
and RFS rates for patients with LP-EX (34.9 and 14.3 %,
respectively) were considerably worse than for patients
with LP-LNM (61.1 and 33.8 %, respectively). Further-
more, we found that the 5-year OS rate for the patients with
LP-EX (34.9 %) resembled that for the patients with stage
3C disease (33.4 %), as demonstrated in the AJCC 7th
edition.10 We have provided the first clarification of the
clinical significance of LP-EX, which is sometimes
observed in cases of low rectal cancer.
The current study showed that both the OS and RFS
rates were significantly worse in the LP-EX group than in
the other groups. Moreover, distant recurrences were sig-
nificantly more common in the LP-EX group than in the
other groups, although no significant difference in local
recurrences was observed between the LP-EX group and
the other groups. The high incidence of distant recurrence
may be one of the reasons why the LP-EX group had a poor
prognosis, indicating that LP-EX might be a systemic
disease rather than a local disease. We consider aggressive
adjuvant chemotherapy to be essential for patients with LP-
EX and recommend that oxaliplatin-based adjuvant
chemotherapy such as FOLFOX or CapeOX should be
applied for these patients to improve their oncologic
outcome.1
This study had three main limitations. First, this was a
retrospective study conducted at two institutions and thus
was subject to various biases. Second, the incidence of
LPLN metastasis might have been underestimated in the
current study because we examined only the harvested
LPLN tissue rather than all the tissue from the LPLN area.
Third, this study did not include patients who underwent
NACRT, which is regarded as the standard treatment in
Western countries. Additional research is needed to explore
LP-EX from other perspectives, for example, in terms of its
clinical significance after NACRT.
In conclusion, LP-EX is a useful pathologic parameter
that can be used to stratify patients with metastasis in the
LPLN area.
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